Search Results
May 07, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 01, 2026, 17:10 ET Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.So What: If you purchased ADMA Biologics securities you may be entitled to compensation
More news about: THE ROSEN LAW FIRM, P. A.
Apr 30, 2026, 22:40 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Apr 25, 2026, 08:09 ET Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.So What: If you purchased ADMA Biologics securities you may be entitled to compensation
More news about: THE ROSEN LAW FIRM, P. A.
Apr 23, 2026, 01:02 ET Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Sportradar Group AG
investigating possible securities fraud claims against Sportradar (Nasdaq: SRAD). The investigation results from inaccurate statements ADMA may have made regarding its financial statements, business operations and prospects.
More news about: Ademi LLP
Apr 21, 2026, 09:30 ET ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
ADMA Investors with Losses Encouraged to Contact the FirmSAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16%
More news about: Hagens Berman Sobol Shapiro LLP
Apr 20, 2026, 18:29 ET Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.So What: If you purchased ADMA Biologics securities you may be entitled to compensation
More news about: THE ROSEN LAW FIRM, P. A.
Apr 16, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Apr 15, 2026, 13:30 ET Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.So What: If you purchased ADMA Biologics securities you may be entitled to compensation
More news about: THE ROSEN LAW FIRM, P. A.
Apr 15, 2026, 09:00 ET ADMA Investor Alert: ADMA Biologics Securities Fraud Investigation - Investors With Losses May Seek to Lead the Potential Class Action After Company Allegedly Concealed Revenue Headwinds: Levi & Korsinsky
www.zlk.comFrequently Asked Questions About the ADMA InvestigationQ: How much did ADMA stock drop?A: ADMA Biologics shares declined sharply after Culper Research's report was issued in the afternoon of March 24, 2026. From
More news about: Levi & Korsinsky, LLP
Apr 14, 2026, 17:32 ET ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
April 14, 2026 /PRNewswire/ -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's report, "ADMA Biologics Inc. (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and
More news about: Hagens Berman Sobol Shapiro LLP
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Apr 02, 2026, 21:44 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Apr 02, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Apr 01, 2026, 09:00 ET ADMA Investor Alert: ADMA Biologics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Revenue Headwinds: Levi & Korsinsky
www.zlk.comFrequently Asked Questions About the ADMA LawsuitQ: How much did ADMA stock drop?A: ADMA Biologics shares declined sharply after Culper Research's report was issued in the afternoon of March 24, 2026. From a
More news about: Levi & Korsinsky, LLP
Mar 31, 2026, 06:07 ET ADMA Securities News: ADMA Biologics Investigated for Securities Fraud After Culper Research Report Revelation Sparks 29% Stock Drop
https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.Why is ADMA Biologics Being Investigated for Securities Fraud? ADMA Biologics is an end-to-end commercial biopharmaceutical company
More news about: Bleichmar Fonti & Auld LLP
Mar 30, 2026, 15:47 ET ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
March 30, 2026 /PRNewswire/ -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's report, "ADMA Biologics Inc. (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and
More news about: Hagens Berman Sobol Shapiro LLP
Mar 26, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Mar 25, 2026, 16:01 ET Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against ADMA Biologics, Inc.
25, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against ADMA (NASDAQ: ADMA). The investigation results from inaccurate statements ADMA may have made regarding its financial statements, business operations and prospects.
More news about: Ademi LLP
Mar 24, 2026, 03:31 ET Plasma Fractionation Market to Reach USD 51.06 Billion by 2032, Driven by Rising Demand for Immunoglobulins and Growing Prevalence of Immune Disorders | MarkNtel Advisors
CSL BehringGrifols, S.A.Takeda Pharmaceutical Company LimitedOctapharma AGKedrion BiopharmaADMA Biologics, Inc.Bharat Serums and Vaccines LimitedIntas Pharmaceuticals Ltd.Shanghai RAAS Blood Products Co., Ltd.Merck
More news about: MarkNtel Advisors
Mar 09, 2026, 17:46 ET Global Telehealth Market is Projected to Cross the USD 2 Trillion Mark by 2034, Driven by Digital Healthcare Transformation | DelveInsight
U.S.A. Inc., Novartis AG, ProBioGen AG, TOYOBO CO., LTD., Samsung Biologics, Thermo Fisher Scientific, Inc., AbbVie, Inc., WuXi Biologics, AGC Biologics, ADMA Biologics, Inc., Baxter BioPharma Solutions (Baxter), iBio., Catalent, Inc., Cambrex Corporation, Pfizer Inc., and others.
More news about: DelveInsight Business Research, LLP
Sep 23, 2025, 06:00 ET Bridge to Life Announces the Appointment of Life Sciences Industry Veteran Brian Lenz as Chief Financial Officer
Board of Directors. Prior to joining Bridge to Life, Mr. Lenz spent 12 years at ADMA Biologics, where he served as Chief Financial Officer and General Manager of its subsidiary ADMA BioCenters. Previous to ADMA he was the CFO and COO at CorMedix, and prior, served as CFO in other biotechnology companies.
More news about: Bridge to Life, Ltd.